Tearsheet

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 36%

Low stock price volatility
Vol 12M is 38%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Telehealth Platforms, Show more.

Expensive valuation multiples
P/EPrice/Earnings or Price/(Net Income) is 36x

Key risks
PNTG key risks include [1] an inability to attract and retain the key local leadership essential to its decentralized operating model.

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 36%
1 Low stock price volatility
Vol 12M is 38%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Telehealth Platforms, Show more.
3 Expensive valuation multiples
P/EPrice/Earnings or Price/(Net Income) is 36x
4 Key risks
PNTG key risks include [1] an inability to attract and retain the key local leadership essential to its decentralized operating model.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Pennant (PNTG) stock has gained about 10% since 12/31/2025 because of the following key factors:

1. Pennant Group reported robust financial performance for the fourth quarter and full year 2025, exceeding analyst expectations. The company announced adjusted earnings per share of $0.34 for Q4 2025, surpassing the consensus estimate of $0.31 to $0.32 per share. Total revenue for the fourth quarter reached $289.3 million, beating estimates of $275.2 million by 4.6% and representing a substantial 53.2% increase over the prior year quarter. For the full year 2025, adjusted EPS was $1.18, exceeding the midpoint of their annual guidance, with total revenue growing 36.3% to $947.7 million.

2. The company provided optimistic full-year 2026 guidance, driven by successful strategic acquisitions. Pennant Group projected 2026 annual revenue to be between $1.13 billion and $1.17 billion, which at the midpoint indicates a 22.4% increase over 2025. Adjusted EBITDA for 2026 is anticipated to be between $88.5 million and $94.1 million, reflecting a 26% increase at the midpoint. This positive outlook is largely attributed to the successful integration of major acquisitions, including over 50 home health and hospice locations acquired from UnitedHealth and Amedisys in October 2025 for $146.5 million.

Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 9.2% change in PNTG stock from 12/31/2025 to 4/18/2026 was primarily driven by a 11.9% change in the company's Total Revenues ($ Mil).
(LTM values as of)123120254182026Change
Stock Price ($)28.1530.749.2%
Change Contribution By: 
Total Revenues ($ Mil)84794811.9%
Net Income Margin (%)3.2%3.1%-1.0%
P/E Multiple36.536.0-1.3%
Shares Outstanding (Mil)3535-0.1%
Cumulative Contribution9.2%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/18/2026
ReturnCorrelation
PNTG9.2% 
Market (SPY)-5.4%14.8%
Sector (XLV)-3.9%41.7%

Fundamental Drivers

The 21.9% change in PNTG stock from 9/30/2025 to 4/18/2026 was primarily driven by a 18.6% change in the company's Total Revenues ($ Mil).
(LTM values as of)93020254182026Change
Stock Price ($)25.2230.7421.9%
Change Contribution By: 
Total Revenues ($ Mil)79994818.6%
Net Income Margin (%)3.4%3.1%-7.0%
P/E Multiple32.536.010.9%
Shares Outstanding (Mil)3535-0.3%
Cumulative Contribution21.9%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/18/2026
ReturnCorrelation
PNTG21.9% 
Market (SPY)-2.9%16.8%
Sector (XLV)7.4%36.8%

Fundamental Drivers

The 22.2% change in PNTG stock from 3/31/2025 to 4/18/2026 was primarily driven by a 36.3% change in the company's Total Revenues ($ Mil).
(LTM values as of)33120254182026Change
Stock Price ($)25.1530.7422.2%
Change Contribution By: 
Total Revenues ($ Mil)69594836.3%
Net Income Margin (%)3.2%3.1%-3.8%
P/E Multiple38.236.0-5.8%
Shares Outstanding (Mil)3435-1.0%
Cumulative Contribution22.2%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/18/2026
ReturnCorrelation
PNTG22.2% 
Market (SPY)16.3%27.8%
Sector (XLV)3.3%33.8%

Fundamental Drivers

The 115.3% change in PNTG stock from 3/31/2023 to 4/18/2026 was primarily driven by a 122.3% change in the company's Net Income Margin (%).
(LTM values as of)33120234182026Change
Stock Price ($)14.2830.74115.3%
Change Contribution By: 
Total Revenues ($ Mil)473948100.3%
Net Income Margin (%)1.4%3.1%122.3%
P/E Multiple63.936.0-43.7%
Shares Outstanding (Mil)3035-14.2%
Cumulative Contribution115.3%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/18/2026
ReturnCorrelation
PNTG115.3% 
Market (SPY)63.3%28.5%
Sector (XLV)20.3%27.9%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
PNTG Return-60%-52%27%91%6%8%-48%
Peers Return3%-16%24%1%26%14%56%
S&P 500 Return27%-19%24%23%16%3%87%

Monthly Win Rates [3]
PNTG Win Rate17%50%50%67%67%25% 
Peers Win Rate50%41%55%52%60%45% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
PNTG Max Drawdown-67%-60%-6%0%-17%-3% 
Peers Max Drawdown-18%-31%-18%-13%-17%-6% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-7% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: ENSG, ADUS, BKD, CHE, EHAB.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/17/2026 (YTD)

How Low Can It Go

Unique KeyEventPNTGS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-86.3%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven628.1%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-69.4%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven226.5%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven147 days148 days

Compare to ENSG, ADUS, BKD, CHE, EHAB

In The Past

Pennant's stock fell -86.3% during the 2022 Inflation Shock from a high on 1/6/2021. A -86.3% loss requires a 628.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Pennant (PNTG)

The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors, who are independent or who require some support. As of December 31, 2021, the company operated 88 home health and hospice agencies, and 54 senior living communities with 4127 Senior Living units in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The Pennant Group, Inc. was incorporated in 2019 and is headquartered in Eagle, Idaho.

AI Analysis | Feedback

Pennant is like a regional operator that combines the senior living facilities of **Brookdale Senior Living** with the home health and hospice services of **Amedisys**.

Think of Pennant as offering a comprehensive range of senior care, from residential communities (similar to **Brookdale Senior Living**) to in-home medical and hospice support (akin to **LHC Group**).

AI Analysis | Feedback

  • Home Health Services: Provides clinical services such as nursing, therapy, and medical social work for patients in their homes.
  • Hospice Services: Offers clinical care, education, and counseling for terminally ill patients and their families, addressing physical, spiritual, and psychosocial needs.
  • Senior Living Services: Delivers residential accommodations, activities, meals, housekeeping, and daily living assistance for independent or support-requiring seniors.

AI Analysis | Feedback

The Pennant Group, Inc. (PNTG) primarily sells its healthcare and senior living services directly to individuals.

Its customer base can be categorized as follows:

  1. Home Health Patients: Individuals who require various clinical services at home, including nursing, speech, occupational and physical therapy, medical social work, and home health aide services.
  2. Hospice Patients and their Families: Terminally ill patients and their families seeking clinical care, education, and counseling services to address their physical, spiritual, and psychosocial needs.
  3. Seniors in Senior Living Communities: Seniors who are independent or require some level of support with daily living, utilizing residential accommodations, activities, meals, housekeeping, and assistance with activities of daily living.

AI Analysis | Feedback

null

AI Analysis | Feedback

Brent J. Guerisoli, Chief Executive Officer and Chairman of the Board

Brent J. Guerisoli was appointed Chief Executive Officer of The Pennant Group, Inc. effective August 1, 2022, and became Chairman of the Board on January 1, 2025. He previously served as President of the Company from January 2021 until his appointment as CEO. Prior to that, he was President of Cornerstone Healthcare, Pennant's home health and hospice segment, where he led transformational growth, strong financial performance, and enhanced clinical excellence. Mr. Guerisoli joined the company in 2012 and has made significant contributions to the financial, clinical, and cultural achievements of Cornerstone, playing a key role in leadership recruiting and training. Throughout his tenure, he has developed numerous leaders and directed the organization's growth efforts across several states. Before joining Pennant, Mr. Guerisoli completed an executive training program and served as a business manager at AT&T.

Lynette Walbom, Chief Financial Officer

Lynette Walbom was appointed Chief Financial Officer of The Pennant Group, Inc. on May 22, 2023. Prior to joining Pennant, Ms. Walbom served as Vice President of Financial Reporting and Tax for Raising Cane's Restaurants, LLC, a national restaurant chain that more than doubled in size during her time there. At Raising Cane's, her responsibilities included financial reporting, acquisitions, tax, accounting systems, and equity management. Before her role at Raising Cane's, Ms. Walbom was the Chief Financial Officer of a family office with investments across several industries, including financial services, computer services, real estate development, and franchising. She began her 23-year career in accounting as a public company auditor at Deloitte. She was introduced to Pennant by a board member with whom she had worked for approximately 13 years in his family office.

John J. Gochnour, President and Chief Operating Officer

John J. Gochnour was appointed Chief Operating Officer of Pennant upon its formation in 2019 and subsequently became President of Pennant on August 1, 2022. Before the formation of Pennant, Mr. Gochnour served as Executive Vice President and General Counsel of Cornerstone starting in January 2013. In his current role, he oversees the operational execution across the company's two primary segments and is responsible for supporting field operations and the ongoing development of service center resources.

Kirk S. Cheney, Executive Vice President, General Counsel and Corporate Secretary

Kirk S. Cheney serves as the Company's Executive Vice President, General Counsel, and Corporate Secretary. In this capacity, Mr. Cheney is responsible for overseeing acquisitions, government relations, and the legal, regulatory, and risk management functions for the company. He also leads Pennant's Service Center.

AI Analysis | Feedback

The Pennant Group, Inc. (PNTG) faces several key risks inherent to the healthcare services industry, particularly within its Home Health and Hospice Services and Senior Living Services segments.
  1. Regulatory and Reimbursement Changes: Pennant's operations are highly susceptible to changes in government regulations and reimbursement policies, especially those related to Medicare, which constitutes a significant portion of the company's revenue. Adverse adjustments to Medicare reimbursement rates or policies could directly impact the company's financial stability and profitability. For example, a recent proposal by the Centers for Medicare and Medicaid Services (CMS) to raise Medicare Advantage payments by less than anticipated caused a sector-wide downturn, affecting PNTG's shares.

  2. Staffing Shortages and Rising Labor Costs: Both the home health/hospice and senior living industries are labor-intensive, making them vulnerable to staffing challenges, labor shortages, and increasing wage costs. The company's ability to attract and retain qualified clinical and caregiving staff is crucial for operational efficiency and service quality. High employee turnover, competition for skilled workers, and the potential for increased costs associated with wages and benefits could strain profitability and hinder consistent service delivery.

  3. Integration Risks from Acquisitions and High Debt Levels: Pennant's growth strategy often involves acquisitions, which introduce integration risks. The process of integrating newly acquired locations can lead to operational disruptions, such as "initial noise" and "choppiness in early results," requiring additional support and potentially impacting financial forecasts. Furthermore, funding these acquisitions can lead to increased indebtedness. Pennant's significant debt levels, which exceed its cash on hand, combined with a high net-debt-to-EBITDA ratio, indicate overleveraging, making incremental borrowing more expensive and increasing financial risk, particularly if profitability declines or market conditions worsen.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable markets for Pennant's main products and services in the U.S. are substantial:

Home Health Services: The U.S. home healthcare market size was estimated at USD 162.35 billion in 2024 and is expected to reach USD 381.40 billion by 2033.

Hospice Services: The U.S. hospice market size was estimated at USD 29.92 billion in 2024 and is projected to grow to USD 39.09 billion by 2030.

Senior Living Services: The U.S. senior living market size was exhibited at USD 923.75 billion in 2023 and is projected to reach approximately USD 1,391.23 billion by 2033.

AI Analysis | Feedback

The Pennant Group, Inc. (PNTG) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
  • Strategic Acquisitions and Integration: Pennant has recently completed significant acquisitions, including Signature Healthcare at Home and over 50 locations from UnitedHealth and Amedisys, which are anticipated to be meaningful contributors to revenue in 2026 and beyond. The company is intensely focused on integrating these newly acquired assets and optimizing their performance, which is a key part of its growth strategy.
  • Organic Growth in Home Health and Hospice Services: The home health and hospice segment consistently serves as a primary engine for revenue growth. This growth is fueled by increased home health admissions and a rising hospice average daily census, alongside strong same-store Medicare admissions and an increase in Medicare revenue per episode.
  • Enhanced Senior Living Occupancy and Pricing: The senior living segment is expected to contribute to revenue growth through improved occupancy rates and strategic price increases. Pennant has reported an increase in both all-store and same-store occupancy, coupled with a rise in average monthly revenue per occupied room.
  • Focus on Operational Excellence and Clinical Quality: Pennant's commitment to operational excellence and high clinical quality is a fundamental driver of growth. By delivering strong clinical outcomes, such as higher CMS star ratings, the company aims to be the preferred provider in its communities, attracting more patients and payors, and thereby supporting organic revenue expansion.

AI Analysis | Feedback

Here is a summary of The Pennant Group, Inc.'s (PNTG) capital allocation decisions over the last 3-5 years:

Share Issuance

  • The number of shares issued and outstanding has generally increased over the past few years. As of December 31, 2025, there were 34,878,000 shares issued and outstanding, compared to 34,626,000 shares at December 31, 2024.
  • At December 31, 2024, there were 34,670,000 shares issued and outstanding, which was an increase from 34,373,000 shares issued and outstanding at December 31, 2023.
  • As of February 28, 2022, 28,529,556 shares of common stock were outstanding.

Outbound Investments

  • The company made significant acquisitions, including assets from UnitedHealth Group and Amedisys, reflecting a strategy of growth through acquiring additional operations in existing and new markets.
  • Investing cash outflows in 2025 significantly exceeded operating cash inflows, driven by acquisition-related growth.

Capital Expenditures

  • Capital expenditures for the fourth quarter of 2025 were $3.5 million, an increase of 4.0% year-over-year.
  • For the full year 2025, capital expenditures absorbed a large share of operating cash flow, totaling $12.0 million.
  • Pennant Group invested $3.6 million in capital expenditures in Q4 2025, funding long-term assets and infrastructure.

Better Bets vs. Pennant (PNTG)

Trade Ideas

Select ideas related to PNTG.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG03312026PGNYProgynyDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
0.0%0.0%0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG03272026CNCCenteneDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.3%2.3%-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG03272026OSCROscar HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
3.0%3.0%-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper03202026WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
-0.4%-0.4%-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%03202026GILDGilead SciencesQualityQ | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run
1.6%1.6%-2.2%

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

PNTGENSGADUSBKDCHEEHABMedian
NamePennant Ensign Addus Ho.Brookdal.Chemed Enhabit  
Mkt Price30.74200.1194.3213.74384.6113.7262.53
Mkt Cap1.111.51.73.35.40.72.5
Rev LTM9485,0581,4233,1942,5301,0601,976
Op Inc LTM514251398734164113
FCF LTM36180104173256685
FCF 3Y Avg31185106-303225379
CFO LTM4856411221838871165
CFO 3Y Avg4042911318237957148

Growth & Margins

PNTGENSGADUSBKDCHEEHABMedian
NamePennant Ensign Addus Ho.Brookdal.Chemed Enhabit  
Rev Chg LTM36.3%18.7%23.2%2.2%4.1%2.4%11.4%
Rev Chg 3Y Avg26.3%18.7%14.5%5.2%5.8%-0.3%10.2%
Rev Chg Q53.2%20.2%25.6%-3.4%-0.1%4.7%12.4%
QoQ Delta Rev Chg LTM11.9%4.7%5.6%-0.8%-0.0%1.2%2.9%
Op Inc Chg LTM35.9%18.7%35.0%57.2%-7.0%36.9%35.5%
Op Inc Chg 3Y Avg37.4%15.0%26.7%108.7%-0.4%-0.7%20.9%
Op Mgn LTM5.4%8.4%9.7%2.7%13.5%6.0%7.2%
Op Mgn 3Y Avg5.1%7.9%9.1%1.7%14.6%4.7%6.5%
QoQ Delta Op Mgn LTM0.3%0.1%0.6%0.7%-0.4%0.1%0.2%
CFO/Rev LTM5.1%11.2%7.8%6.8%15.3%6.7%7.3%
CFO/Rev 3Y Avg5.6%9.8%9.5%5.9%15.7%5.4%7.7%
FCF/Rev LTM3.8%3.6%7.3%0.5%12.9%6.2%5.0%
FCF/Rev 3Y Avg4.3%4.4%8.9%-1.0%13.4%5.0%4.7%

Valuation

PNTGENSGADUSBKDCHEEHABMedian
NamePennant Ensign Addus Ho.Brookdal.Chemed Enhabit  
Mkt Cap1.111.51.73.35.40.72.5
P/S1.12.31.21.02.10.71.2
P/Op Inc20.927.112.337.715.810.918.4
P/EBIT20.424.912.1-123.915.019.717.4
P/E36.033.517.8-12.420.3-151.519.1
P/CFO22.120.415.315.013.99.915.2
Total Yield2.8%3.1%5.6%-8.0%5.4%-0.7%2.9%
Dividend Yield0.0%0.1%0.0%0.0%0.4%0.0%0.0%
FCF Yield 3Y Avg4.3%2.5%5.7%-2.6%4.4%11.6%4.4%
D/E0.40.20.11.70.00.70.3
Net D/E0.40.10.11.60.00.70.3

Returns

PNTGENSGADUSBKDCHEEHABMedian
NamePennant Ensign Addus Ho.Brookdal.Chemed Enhabit  
1M Rtn-4.1%-1.1%-5.7%-2.8%-0.1%0.7%-2.0%
3M Rtn5.5%10.9%-12.3%12.6%-14.8%30.4%8.2%
6M Rtn30.0%10.0%-20.3%58.3%-12.5%70.2%20.0%
12M Rtn17.6%56.6%-6.8%120.2%-33.6%78.6%37.1%
3Y Rtn144.9%104.6%-13.8%225.6%-30.6%8.7%56.7%
1M Excs Rtn-15.1%-9.9%-14.7%-11.6%-7.2%-6.7%-10.8%
3M Excs Rtn0.2%6.4%-16.7%19.5%-18.7%23.4%3.3%
6M Excs Rtn20.0%5.7%-25.5%49.1%-18.4%63.0%12.9%
12M Excs Rtn-13.8%23.2%-37.0%89.2%-66.4%44.1%4.7%
3Y Excs Rtn50.7%30.9%-90.1%155.3%-104.2%-71.6%-20.4%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Home Health and Hospice Services515386342310254
Senior Living Services175148131130137
All Other5110  
Total695545473440391


Operating Income by Segment
$ Mil20252024202320222021
Home Health and Hospice Services88 62  
Senior Living Services52 38  
Net income attributable to noncontrolling interest2 1  
Activities associated with transitioning operations1 -6  
Transition services costs0 0  
Start-up operations-0 -1  
Other income-0 0  
Unusual, non-recurring, or redundant charges-1 -1  
Acquisition related costs-1 -1  
Depreciation and amortization-6 -5  
Share-based compensation expense-8 -3  
Rent-cost of services-43 -38  
Unallocated corporate expenses-44    
All Other  -31  
Total38 13  


Price Behavior

Price Behavior
Market Price$30.74 
Market Cap ($ Bil)1.1 
First Trading Date10/01/2019 
Distance from 52W High-10.7% 
   50 Days200 Days
DMA Price$31.79$27.50
DMA Trendupup
Distance from DMA-3.3%11.8%
 3M1YR
Volatility44.4%37.6%
Downside Capture0.140.41
Upside Capture85.1981.24
Correlation (SPY)14.3%27.9%
PNTG Betas & Captures as of 3/31/2026

 1M2M3M6M1Y3Y
Beta0.950.700.560.510.560.74
Up Beta2.360.561.18-0.030.530.55
Down Beta-0.430.25-0.040.460.390.57
Up Capture132%169%100%97%72%109%
Bmk +ve Days7162765139424
Stock +ve Days11243571131396
Down Capture144%35%53%46%77%97%
Bmk -ve Days12233358110323
Stock -ve Days11182854117345

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PNTG
PNTG18.5%38.0%0.53-
Sector ETF (XLV)9.6%16.0%0.3931.4%
Equity (SPY)21.1%12.9%1.3227.5%
Gold (GLD)50.9%27.5%1.49-2.4%
Commodities (DBC)25.2%16.2%1.40-5.9%
Real Estate (VNQ)17.5%13.7%0.9320.5%
Bitcoin (BTCUSD)-7.8%42.6%-0.085.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PNTG
PNTG-6.0%51.9%0.07-
Sector ETF (XLV)6.4%14.6%0.2527.7%
Equity (SPY)10.8%17.1%0.4933.9%
Gold (GLD)22.6%17.8%1.044.5%
Commodities (DBC)11.6%18.8%0.516.9%
Real Estate (VNQ)4.4%18.8%0.1432.9%
Bitcoin (BTCUSD)5.2%56.5%0.3114.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PNTG
PNTG7.4%63.1%0.44-
Sector ETF (XLV)9.8%16.5%0.4833.2%
Equity (SPY)14.0%17.9%0.6739.8%
Gold (GLD)14.3%15.9%0.758.8%
Commodities (DBC)8.5%17.6%0.4017.5%
Real Estate (VNQ)5.6%20.7%0.2439.7%
Bitcoin (BTCUSD)68.4%66.9%1.0719.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date3312026
Short Interest: Shares Quantity0.8 Mil
Short Interest: % Change Since 3152026-24.0%
Average Daily Volume0.2 Mil
Days-to-Cover Short Interest3.4 days
Basic Shares Quantity34.6 Mil
Short % of Basic Shares2.3%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
2/25/2026-7.9%1.4%-7.6%
11/5/2025-5.6%0.3%14.5%
8/6/20258.4%17.2%9.1%
2/27/2025-10.8%-9.6%-3.6%
11/6/2024-3.4%-1.0%-9.7%
8/6/2024-1.9%7.4%15.8%
2/28/202410.5%12.0%16.3%
11/7/20238.1%11.6%14.1%
...
SUMMARY STATS   
# Positive81213
# Negative14109
Median Positive10.6%11.8%14.5%
Median Negative-7.3%-14.0%-12.8%
Max Positive40.7%49.8%41.8%
Max Negative-23.3%-34.9%-49.1%

SEC Filings

Expand for More
Report DateFiling DateFiling
12/31/202502/26/202610-K
09/30/202511/05/202510-Q
06/30/202508/06/202510-Q
03/31/202505/06/202510-Q
12/31/202402/27/202510-K
09/30/202411/06/202410-Q
06/30/202408/06/202410-Q
03/31/202405/06/202410-Q
12/31/202302/28/202410-K
09/30/202311/07/202310-Q
06/30/202308/08/202310-Q
03/31/202305/04/202310-Q
12/31/202202/23/202310-K
09/30/202211/07/202210-Q
06/30/202208/08/202210-Q
03/31/202205/09/202210-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 2/25/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Revenue1.13 Bil1.15 Bil1.17 Bil23.9% Higher NewActual: 930.00 Mil for 2025
2026 Adjusted EPS1.261.311.3612.9% Higher NewActual: 1.16 for 2025
2026 Adjusted EBITDA88.50 Mil91.30 Mil94.10 Mil26.2% Higher NewActual: 72.35 Mil for 2025
2026 Adjusted EBITDA prior to NCI94.20 Mil97.10 Mil100.00 Mil   

Prior: Q3 2025 Earnings Reported 11/5/2025

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2025 Total Revenue911.40 Mil930.00 Mil948.60 Mil6.9% RaisedGuidance: 870.20 Mil for 2025
2025 Adjusted Earnings Per Diluted Share1.141.161.183.6% RaisedGuidance: 1.12 for 2025
2025 Adjusted EBITDA70.90 Mil72.35 Mil73.80 Mil2.0% RaisedGuidance: 70.90 Mil for 2025

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Cheney, Kirk SterlingEVP, GC and Corp SecyDirectSell807202523.3488020,539306,221Form
2Guerisoli, BrentChief Executive OfficerDirectSell731202523.343,99593,2311,913,121Form
3Stringfield, Joanne DirectSell523202529.475,000147,350892,204Form
4Stringfield, Joanne DirectSell505202525.6266517,037775,646Form